Outcomes of Kahook Dual Blade Goniotomy for Uveitis Associated Open Angle Glaucoma or Ocular Hypertension.
Miller Victoria J, Patnaik Jennifer L, Young Cara E Capitena, SooHoo Jeffrey R, Seibold Leonard K, Kahook Malik Y, Ertel Monica K, Palestine Alan G, Pantcheva Mina B
AI Summary
KDB goniotomy for uveitic glaucoma/OHT successfully lowered IOP and reduced medication use in some patients, offering a potential surgical option for these challenging cases.
Abstract
Prcis: Kahook Dual Blade (KDB) goniotomy can successfully lower intraocular pressure in some patients with uveitis-associated ocular hypertension or glaucoma.
Purpose
The purpose of this study was to report a case series of patients that underwent KDB goniotomy at a single institution for uveitis-associated ocular hypertension or glaucoma with an open angle.
Methods
We performed a retrospective chart review of all patients with uveitis-associated ocular hypertension or glaucoma who underwent KDB goniotomy with trabecular meshwork excision alone or in combination with phacoemulsification cataract surgery at a single center between August 2017 and February 2020. The case series included 45 eyes of 37 patients. All eyes developed ocular hypertension refractory to maximum-tolerated medical therapy and required surgical intervention. Two eyes were excluded as they were lost to follow-up before 5 months postoperatively. Surgical success was defined as reaching the goal intraocular pressure or lower for each patient, including ongoing medical therapy.
Results
At most recent follow-up, 25 (55.6%) of 45 eyes had an intraocular pressure that was at goal. Mean follow-up time was 15.2±12.1 months ranging from 0.5 to 36 months postoperatively, considering that patients were eliminated from the data analysis once they required a second surgery. The mean number of preoperative medications, including oral carbonic anhydrase inhibitors was 3.7±1.2 medications. The mean number of postoperative medications through the last clinic visit was 2.5±1.9 medications for a mean reduction of 1.2±1.6 medications ( P -value <0.0001*).
Conclusions
This larger case series shows that some patients with uveitis-associated ocular hypertension or glaucoma with an open angle may have success with KDB goniotomy.
MeSH Terms
Shields Classification
Key Concepts5
Kahook Dual Blade (KDB) goniotomy can successfully lower intraocular pressure in some patients with uveitis-associated ocular hypertension or glaucoma.
At most recent follow-up, 25 (55.6%) of 45 eyes that underwent Kahook Dual Blade (KDB) goniotomy for uveitis-associated ocular hypertension or glaucoma had an intraocular pressure that was at goal.
The mean number of postoperative medications through the last clinic visit for patients undergoing Kahook Dual Blade (KDB) goniotomy for uveitis-associated ocular hypertension or glaucoma was 2.5±1.9 medications, representing a mean reduction of 1.2±1.6 medications (P-value <0.0001*).
The mean number of preoperative medications, including oral carbonic anhydrase inhibitors, for patients undergoing Kahook Dual Blade (KDB) goniotomy for uveitis-associated ocular hypertension or glaucoma was 3.7±1.2 medications.
A retrospective chart review was performed on 45 eyes of 37 patients with uveitis-associated ocular hypertension or glaucoma who underwent Kahook Dual Blade (KDB) goniotomy between August 2017 and February 2020, with a mean follow-up time of 15.2±12.1 months.
Related Articles5
XEN ® -45 implantation for refractory uveitic glaucoma.
Case SeriesGonioscopy-assisted transluminal trabeculotomy is an effective surgical treatment for uveitic glaucoma.
Case SeriesClinical analysis of supraciliary effusion development following gonioscopy-assisted transluminal trabeculotomy surgery for pseudoexfoliation glaucoma.
Observational StudyGonioscopy-Assisted Transluminal Trabeculotomy in Uveitis-Related Ocular Hypertension and Glaucoma.
Case SeriesBilateral Acute Iris Transillumination and Elevated Intraocular Pressure After COVID-19 Infection.
Case SeriesIs this article assigned to the wrong chapter(s)? Let us know.